# This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

> **NCT03968419** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Canakinumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03968419
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-05
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-08-15
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Study early terminated due to low enrollment compared to the anticipated figures.
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03968419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03968419, "This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03968419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*